Expert Ratings For Arvinas
Within the last quarter, Arvinas (NASDAQ:ARVN) has observed the following analyst ratings:
Stifel Initiates Coverage On Arvinas with Buy Rating, Announces Price Target of $115
Stifel analyst Bradley Canino initiates coverage on Arvinas (NASDAQ:ARVN) with a Buy rating and announces Price Target of $115.
Analyst Ratings For Arvinas
Over the past 3 months, 5 analysts have published their opinion on Arvinas (NASDAQ:ARVN) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
B of A Securities Initiates Coverage On Arvinas with Buy Rating, Announces Price Target of $110
B of A Securities analyst Tazeen Ahmad initiates coverage on Arvinas (NASDAQ:ARVN) with a Buy rating and announces Price Target of $110.
Roth Capital Maintains Buy on Arvinas, Raises Price Target to $135
Roth Capital analyst Zegbeh Jallah maintains Arvinas (NASDAQ:ARVN) with a Buy and raises the price target from $120 to $135.
Arvinas And Insilico Medicine Announce R&D Collaboration
Insilico Medicine is proud to announce an R&D collaboration with Arvinas (NASDAQ:ARVN). This strategic partnership will involve Insilico Medicine's AI-augmented platforms and close cooperation between
Arvinas Q2 EPS $(1.03) Down From $(0.65) YoY, Sales $5.54M Down From $5.75M YoY
Arvinas (NASDAQ:ARVN) reported quarterly losses of $(1.03) per share. This is a 58.46 percent decrease over losses of $(0.65) per share from the same period last year. The company reported $5.54 million in sales this
The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam’s Clinical Collaboration, 4 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 29)